尿囊素铝预防非甾体类抗炎药相关性溃疡疗效观察

目的:探讨尿囊素铝片预防非甾体类抗炎药(NSAIDs)相关性溃疡的临床疗效及安全性。方法:107例患者按随机数字表分为尿囊素铝组53例(予尿囊素铝片0.1 g,po tid),雷贝拉唑组54例(予雷贝拉唑肠溶胶囊20 mg,po qd),疗程均8周,观察两组临床疗效和不良反应。结果:用药8周末,尿囊素铝组消化性溃疡发生率5.66%,雷贝拉唑组消化性溃疡发生率7.41%,差异无统计学意义(P>0.05);两组药物不良反应发生率分别为3.77%和5.56%,差异也无统计学意义(P>0.05)。而尿囊素铝组药物费用显著低于雷贝拉唑组,差异有统计学意义(P<0.05)。结论:尿囊素铝预防NSAIDs相关性溃疡安全、有效、经济,值得临床使用。

Analysis of the Efficacy of Aldioxa Preventing Non steroidal Anti inflammatory Drugs Induced Peptic Ulcer

Objective：To discuss the efficacy and safety of the prevention of aldioxa tablets of non-steroidal anti-inflammatory drugs（NSAIDs） induced peptic ulcer.Methods：107 eligible patients were randomly divided into aldioxa group（53 cases,0.1g each time,three times a day orally） and rabeprazole group（54 cases,20mg each time,once a day orally）.The courses of the treatment of both groups were 8 weeks.The clinical efficacy and safety of two drugs were observed.Results：The morbidity of peptic ulcer of the aldioxa group was 5.66% after 8 weeks,while the rabeprazole group was 7.44%.There were no significant differences between the two groups（P0.05）.The incidences of ADR of the aldioxa group and rabeprazole group were 3.77% and 5.56%（P0.05）.The difference between the two groups had no statistical significance.The cost of the aldioxa group was significantly lower than that of the rabeprazole group（P0.05）.Conclusion：Aldioxa was an economic,safe,effective drug in the prevention of NSAIDs induced ulcer drugs and worthy of clinical application.